Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Selected as a solid growth name with raised 2025 guidance supported by strong diagnostic product adoption and margin expansion; upcoming Nov 3 Q3 earnings represent key catalyst amid moderate technical weakness requiring caution.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Margins ⢠Robust Cash Flow ⢠Rising Leverage IDXX delivers exceptional profitability and cash flow, but elevated valuation, tightening liquidity, and rising leverage warrant caution.
Price Behavior
Key Price Behavior Insights: ⢠Monthly decline ⢠Support bounce ⢠Resistance overhead Support Level: $529â$535 Resistance Level: $545â$556 IDXX remains bearish over the last month, with a tentative bounce at $529â$535 but recovery requiring sustained closes above $556.
Sentiment & News
Key News Insights: ⢠Raised Outlook ⢠Diagnostics Growth ⢠Valuation Risk IDEXX's strong diagnostic growth, raised outlook, and innovation pipeline support momentum, though premium valuation and recent share weakness remain key risks.
AI Summary
IDXX remains an elite cash-generative diagnostics compounder, but at ~39â41x earnings the actionable thesis is to buy only if companion-animal testing, international growth, and software/AI adoption sustain near-double-digit organic growth; softer veterinary traffic or stalled margins could trigger a sharper valuation de-rating.
Description
IDEXX Laboratories develops, manufactures, and sells diagnostic instruments, consumables, laboratory services, and practice management software for veterinary, livestock, dairy and water-testing markets worldwide. Its offerings include point-of-care and reference laboratory diagnostics, imaging and monitoring systems, and microbiological water tests, supported by sales, technical service teams and distribution partners. The company also supplies certain human point-of-care analyzers; it was founded in 1983 and is headquartered in Westbrook, Maine.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Nov 3 | Nov 10 | IDXX | IDEXX Laboratories, Inc. | Selected as a solid growth name with raised 2025 guidance supported by strong diagnostic product adoption and margin expansion; upcoming Nov 3 Q3 earnings represent key catalyst amid moderate technical weakness requiring caution. | Closed | -1.8% |